News & Media

Press release
Interim Report, January – June 2014*

Financial summary for the second quarter Net turnover totalled SEK 564.0 million (SEK 40.7 m), of which SEK 500.7 million was...

Read more
Press release
Niklas Prager appointed new President and CEO of Medivir

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the company’s Board of Directors has appointed Niklas Prager as new...

Read more
Press release
Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that it has entered a license agreement with Boehringer Ingelheim International GmbH...

Read more
Press release
Phase II COSMOS study results published in The Lancet on World Hepatitis Day

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that results from the phase II COSMOS clinical study were published July 28...

Read more
Press release
U.S. FDA has granted Priority Review for OLYSIO® in combination with sofosbuvir supplementary New Drug Application

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the Food and Drug Administration (FDA) has assigned a Priority Review designation...

Read more
Press release
Continued strong market uptake for OLYSIO® during the second quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the global second quarter net sales of Olysio (simeprevir) amounted to 831...

Read more
Press release
OLYSIO™ available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection

Treatment of hepatitis C patients with Olysio (simeprevir) has begun in Sweden, Finland and Denmark Stockholm, Sweden — Medivir AB (OMX:...

Read more
Press release
Simeprevir approved in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

OLYSIO™ (Simeprevir) provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment...

Read more
Press release
Resolutions at the annual general meeting in Medivir on 8 May 2014

Election of the board of directors and auditorThe annual general meeting in Medivir Aktiebolag (publ) on 8 May 2014 resolved, in...

Read more
Press release
Interim Report, January – March 2014*

Financial summary for the first quarter Net turnover totalled SEK 208.2 million (SEK 178.1 m), SEK 161.7 million of which comprised...

Read more
Press release
A supplemental New Drug Application has been submitted to the U.S. FDA for Simeprevir in combination with Sofosbuvir

The Supplemental New Drug Application for OLYSIO™ (simeprevir) for once-daily use in combination with sofosbuvir is for 12 Weeks treatment of...

Read more
Press release
Adasuve will now be launched in Sweden, Norway, Finland and Denmark

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that Adasuve now will be launched for the treatment of mild to moderate...

Read more